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Nearly 20% of the diabetic population suffers from a sub-threshold depression 
without meeting the criteria of a major depression. However, elevated depressive 
symptoms are associated with a reduced quality of life, lower self-care activities, and 
a higher mortality. To target this large group of people, a diabetes-specific treatment 
program (DIAMOS) was developed and evaluated in a randomized controlled trial 
with a 12-month follow-up.
DIAMOS is a group program based on cognitive-behavioral-therapy (CBT). It consists 
of 5 group sessions which lasts for 90 minutes each. 214 inpatients with subclini-
cal depression were randomized either to DIAMOS or to a control group receiving 
diabetes education. Depression, diabetes-related distress, and quality of life were 
assessed via questionnaires (CES-D, PAID, WHO-5 respectively). HbA1c was analyzed 
in a central laboratory.
181 patients (age: 43±14 yrs.; 57% female; 63% Type 1 DM; diabetes duration 15±14 
yrs.; 95% with insulin; 51% with late complications; HbA1c 8.8±1.7%; CES-D 23.3±8.1; 
PAID 39.5±18.4; WHO-5 8.9±4.5) were available at the 12-month follow-up (drop-out 
rate: 15%). Compared to the control group, patients treated with DIAMOS showed a 
significantly greater reduction of depressive symptoms (- 7.4 ± 11.4 vs. - 2.7 ± 11.7; 
p < .01), and diabetes-related distress (- 13.0 ± 18.9 vs. - 4.2 ± 16.9; p < .01). Impro-
vement of quality of life (+ 4.5 ± 6.1 vs. + 2.5 ± 6.3; p > .05) as well as HbA1c impro-
vement was comparable in both groups.
The results demonstrate that DIAMOS is an effective tool for the treatment of sub-
clinical depression in people with diabetes. In addition, DIAMOS positively affects di-
abetes-related distress and quality of life. Interestingly, the reduction of depressive 
symptoms and distress was not associated with an improvement of glycemic control. 
DIAMOS proofs to be an innovative tool for routine care to improve the situation of 
people with diabetes and subclinical depression.
Table 1:   Sample Characteristics
A B S T R A C T
Patients with diabetes are almost twice as likely affected by depressive disorders. Recent 
meta-analyses demonstrated that nearly 12% of patients with diabetes are affected by 
major depression and an additional 20% are suffering from sub-threshold depression. Sub-
threshold depression is defined as having elevated depressive symptoms without meeting 
diagnostic criteria for major depression. Serious adverse effects of depression in people with 
diabetes are reported throughout the literature, but strikingly also sub-threshold depression 
is linked with a poorer quality of life, higher diabetes-related distress, reduced diabetes 
self-care, and higher risks of micro- or macrovascular diabetes complications, disability, 
and early mortality. The epidemiological findings regarding the high frequency of sub-
threshold depression and the evidence of its negative impact on the prognosis of diabetes 
support the need for adequately addressing sub-threshold depression in clinical care. To 
target this large group of people, a diabetes-specific treatment program (DIAMOS) was 
developed and evaluated in a randomized controlled trial with a 12-month follow-up.
I N T R O D U C T I O N
C O N C L U S I O N
R E S U L T S
M E T H O D S
People with diabetes and sub-threshold depression were randomly 
assigned to either the newly developed intervention program DIAMOS or to the 
control group (CG). Patients in the CG participated in a standard group based 
diabetes education program of 5 lessons (90 minutes each) including topics such as healthy 
diet in diabetes, diabetes and exercise, and diabetes and legal issues. The program was 
conducted by diabetes educators. DIAMOS is based on a self-management/empower-
ment approach focusing on the coping with diabetes-related distress. It is conducted as a 
group program comprising 5 lessons of 90 minutes each, led by a certified psychologist. 
Primary outcome was the reduction in depressive symptoms assessed via the CES-D questi-
onnaire. Secondary outcomes were incidence of depressive disorders assessed via the PHQ-9 
• A total of 3,156 patients with diabetes were screened for depressive symptoms, 1,261 
of those were screened positive. 214 of those positively screened met the inclusion 
criteria and gave informed consent. 108 patients were randomized to the CG and 106 
to DIAMOS. A total of 33 patients (15.4%) were lost to follow-up (see figure 1).
• Patients in both groups were 43 years old with mean diabetes duration of 14 years 
(no differences between groups). Sex distribution in both groups was similar. People 
with type 1 diabetes were rather frequent in both groups with a significantly higher 
proportion in the CG. Moderate overweight was present in both groups, but in CG 
BMI was significantly lower than in DIAMOS. Glycemic control was comparably poor in 
both groups. The prevalence of microvascular complications did not differ significantly 
between groups, whereas the prevalence of macrovascular complications was signifi-
cantly higher in DIAMOS (see table 1).
• Participants of DIAMOS reported significantly more depressive symptoms but well-
being and diabetes-related distress did not differ at baseline between both groups 
(see table 2).
Primary Outcome:
• Depressive symptoms as measured by the CES-D could be reduced in both groups 
(-7.4 ± 11.4 vs. -2.7 ± 11.7; both p
within
 < .05) (see figure 2). However, the reduction of 
depressive symptoms in DIAMOS was significantly greater than the reduction in the 
CG (adjusted-Δ 3.7 ± 1.6, 95% CI 0.6 to 6.8) even when adjusting for baseline scores, 
BMI, and diabetes type (see figure 2).
• An intention-to-treat analysis also showed a significant difference between CG and 
DIAMOS in favor of DIAMOS (p=0.049) (see figure 3).
Secondary Outcomes:
• Patients in DIAMOS also showed a significantly greater reduction of the PHQ-9 
depression score (-3.3 ± 5.1 vs. -1.2 ± 5.7; both p
within
 < .05; adjusted-Δ 1.5 ± 0.7, 95% 
CI 0.1 to 2.9) (see figure 4), corroborating the finding of a significant reduction of de-
pressive symptoms measured by the CES-D. 
• Diabetes-related distress was significantly reduced in both groups (-13.0 ± 18.9 vs. 
-4.2 ± 16.9; both p
within
 < .05), but DIAMOS led to a significantly greater reduction of 
diabetes-related distress (adjusted-Δ 8.0 ± 2.4, 95% CI 3.3 to 12.7) as measured by the 
PAID (see figure 5).
• Improved well-being was reported in DIAMOS as well as in the CG (+4.5 ± 6.1 vs. +2.5 ± 
6.3; both p
within
 < .05). However, the difference of improvement in well-being between 
both groups did not reach significance (adjusted-Δ -1.1 ± 0.8, 95% CI 0.5 to -2.8) (see 
figure 6). 
• Interestingly, there was a significant improvement in glycemic control in both groups 
(-0.5 ± 2.0 vs. -0.7 ± 1.7; both p
within 
< .05), but no significant difference between 
DIAMOS and the CG (adjusted-Δ -0.3 ± 0.2, 95% CI 0.2 to -0.7) (see figure 7).
• Furthermore, categorical assessment of major depression according to DSM-IV 
criteria was carried out using the PHQ-9. Based on this analysis, 10 participants of 
DIAMOS (10.8%) versus 20 participants of the CG (22.7%) fulfilled criteria for major 
depression at follow-up (p < .05). Therefore, participating in DIAMOS led to a risk re-
duction of 37% regarding the incidence of major depression (adjusted odds ratio 0.63, 
95% CI 0.42 to 0.96, p < .05).
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Fig. 1:  Study flow chart
Fig. 2:   Reduction of depressive symptoms (CES-D)
questionnaire, diabetes-related distress (PAID questionnaire), quality of life (WHO-5 
questionnaire), and glycemic control (HbA1c was analyzed in a central laboratory).
Fig. 3: Reduction of depressive symptoms (CES-D) in per-protocol and intention-to-treat analyses (adjusted 
mean differences and 95% confidence intervals)
In contrast to routine care, the newly developed program DIAMOS led to significant im-
provements of depressive symptoms, diabetes-related distress and incident depres-
sion one year after participation. Furthermore, subsequent analyses showed that DIA-
MOS has the effect of preventing a deterioration of sub-threshold depression into major 
Table 2:   Psychological variables - baseline characteristics
Fig. 4:  Reduction of depressive symptoms (PHQ-9) Fig. 5:  Reduction of diabetes-related distress (PAID)
1 mean ± standard deviation; ² Mean adjusted between group baseline-endpoint-change adjusted for BMI,  
diabetes type, and baseline values 
Fig.6:  Improvement of emotional well-being (WHO-5) Fig. 7:  Reduction of depressive symptoms (PHQ-9) 
depression. In summary, the DIAMOS program has proven its efficacy in treating sub-
threshold depression and elevated diabetes distress more efficiently than diabetes edu-
cation alone. Given the negative sequelae of sub-threshold depression on the prognosis 
of diabetes, this new program has the potential to close an important gap in the manage-
ment of sub-threshold depression in clinical care.
